Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...

The ClinicalTrials.Gov Support Team expanded outreach efforts to study teams and launched a series of how-to videos to answer frequently asked questions. Northwestern Medicine’s Clinical Research Unit ...

The report was largely positive, but did find there were issues with staff shortages and a lack of Māori input.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

A clinical trial is one that involves human participants and seeks to answer specific questions about a type of medical intervention. This can be a drug or other type of treatment, such as nutritional ...

DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence-based Clinical Trial Solutions for Patient Matching - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's ...

Correspondence to Dr Thomas Bandholm, Dept of Clinical Research, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre DK-2650, Denmark; thomas.quaade.bandholm{at}regionh.dk The REPORT guide ...

Evaluation reports make recommendations intended to help the Government of Canada design and deliver programs and services that are accountable, focused on results, and meet the needs of Canadian ...

DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical ...

All data were collected in an electronic case report form and independently monitored by a clinical research organization ... The anatomical results were assessed at 12 months, with the evaluation of ...

WATERTOWN, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...

Significant clinical improvements in both open label and pediatric ... the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S.